Australian and US Patents Granted

MLS Bio Secures US and Australian Patents for Lead Oncology and Antiviral Programs

MLS Bio is pleased to announce a major milestone in the company’s growth, with the granting of foundational patents in both the United States and Australia. These patents provide composition of matter protection for MLS Bio’s lead assets MLS-269 (oncology) and MLS-289 (antivirals), securing exclusivity through 2041 with pathways for further extensions of up to 20 years.

Developed in collaboration with intellectual property specialists FB Rice, MLS Bio’s targeted IP strategy ensures strong protection of its pipeline across oncology and virology while aligning global filings with future clinical milestones.

MLS-269 is advancing towards clinical development with an initial focus on prostate cancer, one of the most urgent unmet needs in oncology. MLS-289, meanwhile, is being developed as a broad-spectrum antiviral, with multiple applications in high-burden viral diseases.

“This is a foundational step for MLS Bio,” said Penelope Lane, Chief Executive Officer & Managing Director. “Our US and Australian patents strengthen the protection around our pipeline and validate the sophistication of our global IP strategy as we advance toward clinical development and partnerships. Importantly, this protection underpins long-term value creation by securing market exclusivity, enhancing asset attractiveness, and supporting sustained growth for both patients and investors.”

The company continues to progress additional filings across Canada, Europe and APAC, building a globally integrated patent strategy to support its mission of delivering transformative therapies for significant unmet needs.